Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418384 | 0.84 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL7366919 | 0.80 | CYP19A1 (0.44) | SMN1; SMN2CYP19A1ADRB1ADRB3KMT2A | |
| SCHEMBL27760547 | 0.80 | CYP19A1 (0.51) | CYP19A1ADRB1ADRB3KMT2ACYP1A2 | |
| SCHEMBL28710549 | 0.79 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29506741 | 0.79 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2SIGMAR1 | |
| SCHEMBL5051459 | 0.79 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2SIGMAR1 | |
| SCHEMBL29506739 | 0.79 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6800143 | 0.79 | OPRD1 (0.43) | RAB9ANPC1SMN1; SMN2ADRB1ADRB3 | |
| SCHEMBL28309035 | 0.78 | KLKB1 (0.49) | RAB9ANPC1SMN1; SMN2FAAH | |
| SCHEMBL12803743 | 0.78 | SMN1; SMN2 (0.51) | RAB9ANPC1SMN1; SMN2KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097508-A1 | Novel heterocyclically substituted amides, their preparation and use | ABBOTT GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6630493-B1 | Inhibitors of capain enzymes useful for the treatment of ischemias of the heart, the kidney or of central nervous system (e.g. \"stroke\"), inflammations, muscular dystrophy, cataracts of the eyes, Alzheimer's disease etc. | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-07 | — | — | US | disclosed |
| CN-1301255-A | Heterocyclically substituted amides, their production and their use | BASF AG (DE) | 2001-06-27 | — | — | CN | disclosed |
| EP-1073638-A1 | HETEROCYCLICALLY SUBSTITUTED AMIDES, THEIR PRODUCTION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054304-A1 | HETEROCYCLICALLY SUBSTITUTED AMIDES, THEIR PRODUCTION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097508-A1 | Novel heterocyclically substituted amides, their preparation and use | CAPN1, CAPNS1, CAPN2 | RAB9A 2537/4885NPC1 1797/4885SMN1; SMN2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.